文献速递技术与安全腹部乳腺US

健康中国志愿者静脉团注声诺维后全氟丁烷的药代动力学研究

Pharmacokinetics of Perfluorobutane after Intra-Venous Bolus Injection of Sonazoid in Healthy Chinese Volunteers.
PubMed 文献 · Ultrasound Med Biol · 2017-03-07

本研究在两组各8名健康中国志愿者中静脉团注临床剂量0.12 μL或0.60 μL微泡/kg体重的声诺维,用气相色谱串联质谱法测定呼出气和血中全氟丁烷浓度并计算药代动力学参数,结果显示全氟丁烷消除迅速,两剂量组药代动力学特征和安全性数据与既往高加索健康志愿者数据相当。

要点

  • 声诺维静脉团注后全氟丁烷血浓度迅速达峰并快速消除。
  • 0.12 μL微泡/kg组血中全氟丁烷可定量浓度仅维持注射后10至15分钟。
  • 0.60 μL微泡/kg组可定量浓度维持至注射后60分钟,消除曲线呈双相。

核心结论

  • 中国健康志愿者静脉团注声诺维后全氟丁烷药代动力学特征和安全性数据与既往高加索健康志愿者数据相当。

研究设计与样本

  • 研究为在健康中国志愿者中进行的药代动力学与安全性研究,声诺维按临床剂量0.12 μL或0.60 μL微泡/kg体重静脉团注,分两组、每组8人。
  • 采用经验证的气相色谱串联质谱法分析呼出气和血样本并计算主要药代动力学参数。

诊断标准与关键数值

  • 0.12 μL微泡/kg组血全氟丁烷Cmax为2.3 ± 1.1 ng/g,AUC为10.1 ± 2.7 ng × min/g。
  • 0.60 μL微泡/kg组血全氟丁烷Cmax为19.1 ± 9.2 ng/g,AUC为90.1 ± 38.3 ng × min/g。
  • 0.12 μL微泡/kg组呼出气全氟丁烷Cmax为0.35 ± 0.2 ng/mL,0.60 μL微泡/kg组为2.4 ± 0.7 ng/mL。
  • 0.12 μL微泡/kg组血中全氟丁烷可定量浓度仅见于注射后10至15分钟,0.60 μL微泡/kg组见于注射后60分钟且消除曲线提示双相消除。
  • 实验室指标、生命体征、血氧饱和度和心电图评估未见提示需要关注的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Sonazoid is an ultrasound contrast agent based on microbubbles (MB) containing perfluorobutane (PFB) gas. Sonazoid is approved in Japan, Korea and Norway for contrast-enhanced ultrasonography of focal liver lesions and focal breast lesions (Japan only). The objective of this study was to determine the pharmacokinetics (PKs) and safety of Sonazoid in Chinese healthy volunteers (HVs) and to evaluate the potential for ethnic differences in PKs between Chinese and Caucasian HVs. Sonazoid was administered as an intra-venous bolus injection at the clinical dose of 0.12 μL or 0.60 μL MB/kg body weight to two groups of eight Chinese HVs. Expired air and blood samples were collected and analyzed using a validated gas chromatographic tandem mass spectrometry method, and the main PK parameters were calculated. The highest PFB concentrations in blood were observed shortly after intra-venous administration of Sonazoid, and elimination of PFB was rapid. In the 0.12 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for only 10 to 15 min post-injection. In the 0.60 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for 60 min post-injection, and the shape of the elimination curve suggested a biphasic elimination profile. The maximum observed concentration (Cmax) values of PFB in blood were 2.3 ± 1.1 and 19.1 ± 9.2 ng/g for the 0.12 and 0.60 μL MB/kg body weight dose groups (mean ± standard deviation). Area under the curve values were 10.1 ± 2.7 and 90.1 ± 38.3 ng × min/g for the 0.12 and 0.60 μL MB/kg body weight dose groups. Cmax values of PFB in exhaled air were 0.35 ± 0.2 and 2.4 ± 0.7 ng/mL for the 0.12 and 0.60 μL MB/kg body weight dose groups. Assessment of laboratory parameters, vital signs, oxygen saturation and electrocardiograms revealed no changes indicative of a concern. The PK profile and safety data generated in the Chinese HVs were comparable to previous data for Caucasian HVs.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Li P, Hoppmann S, Du P, et al. Pharmacokinetics of Perfluorobutane after Intra-Venous Bolus Injection of Sonazoid in Healthy Chinese Volunteers. Ultrasound Med Biol. 2017. PMID: 28283327. doi:10.1016/j.ultrasmedbio.2017.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。